Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,159.0
16.8 (0.53%)

 

  • STI Straits Times Index
    3,159.0
    16.8 (0.53%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,502.8
    12.7 (0.85%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,893.2
    72.3 (0.27%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,013.1
    -18.2 (-0.60%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    22,605.4
    -781.3 (-3.34%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    5,792.4
    -14.7 (-0.25%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 958.5M
  • Value: 1,079.5M
  • Rise: 167
  • Fall: 154
  • Unch: 493

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Rex Intl0.194+0.016
IPS Securex0.090+0.017
AusGroup^0.046+0.003
Genting Sing0.860-0.010
Broadway Ind^0.084+0.009
Trendlines0.117+0.008
ESR-REIT0.550+0.005
OEL0.025+0.001
YZJ Shipbldg SGD1.010+0.010
Singtel3.100-

World Indices

World Indices
Name Last Change
Nasdaq 9,221.3 -355.3
HSI 26,893.2 +72.3
HSCEI 10,579.9 +11.6
Jakarta 5,792.4 -14.7
Nikkei 225 22,605.4 -781.3
SSE Comp 3,013.1 -18.2
Shanghai A 3,157.4 -19.0
Shanghai B 242.6 -1.9
KOSPI 2,103.6 +24.6

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

CHEMOCENTRYX INC CHEMOCENTRYX INC
Updated on 24 Feb 2020 (End of trading day)
Last (USD): 47.000 Change: -1.870 High: 47.905 Remarks: -
Change (%): -3.83 Low: 46.290
Open 47.050 Yesterday's Close 48.87
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 514,887 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.65156 Trailing EPS (USD) e -0.87089 NAV (USD) b 1.0619
PE a - Trailing PE f - Price / NAV b 44.2603
Dividend (USD) d - Cash In Hand (USD) g 0.6165 Issued & Paid-up Shares c 58,269,000
Dividend Yield (%) d - Price / Cash In Hand g 76.237 Treasury Shares h -
Beta - 75 Daysi 3.862 R-Squared - 75 Days(%)i 0.05 Market Cap (M) 2,738.643
Beta - 500 Daysi 0.146 R-Squared - 500 Days (%)i 0.01 Enterprise Value (M) 2,589.854
Piotroski F Score 2 Exchange Code CCXI Par Value ( $ ) n.a.
52 Weeks Volatility (%) 146.88 Free Float (%) 68.8
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 07 Nov 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 13 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference CHEMOCENTRYX INC NASDAQ 2,738.643 - - 44.2603 -
Industry Biotechnology NASDAQ 2,434.235 285.776 183.472 5.9012 0.749
Local Peer AMGEN INC NASDAQ 128,507.149 15.309 16.387 13.2851 2.587
Local Peer GILEAD SCIENCES INC NASDAQ 92,291.400 16.919 17.135 4.0747 3.167
Local Peer VERTEX PHARMACEUTICAL NASDAQ 61,449.346 29.312 52.217 10.0981 -
Local Peer BIOGEN INC NASDAQ 56,741.383 12.806 9.636 4.2525 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 46,800.295 19.146 22.119 4.2202 -
Local Peer ILLUMINA INC NASDAQ 41,324.640 50.030 41.242 8.9583 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 21,923.127 282.511 9.118 1.9450 -
Local Peer SEATTLE GENETICS INC NASDAQ 19,982.160 - - 10.6498 -
Local Peer GALAPAGOS NV SPON ADR REPR 1 ORD SHS NASDAQ 15,878.335 - 51.161 5.7448 -
Local Peer INCYTE CORPORATION NASDAQ 17,097.123 156.147 38.257 6.5798 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 16,705.125 - - 5.4336 -
Local Peer ALNYLAM PHARMACEUTICALS INC NASDAQ 13,767.897 - - 9.5698 -
Other Local Peers EXACT SCIENCES CORP (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), 10X GENOMICS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), EXELIXIS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), FIBROGEN INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ALKERMES PLC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), UNIQURE N.V. (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), ALECTOR INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), EPIZYME INC (NASDAQ), VIELA BIO INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), ARVINAS INC (NASDAQ), REGENXBIO INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), CORTEXYME INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), MYRIAD GENETICS INC (NASDAQ), NEXTCURE INC (NASDAQ), BLACK DIAMOND THERAPEUTICS INC (NASDAQ), BEAM THERAPEUTICS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), VERACYTE INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), DERMIRA INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), IMMUNOGEN INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), AVROBIO INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), PRECIGEN INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), RETROPHIN INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), ARDELYX INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), COMPUGEN (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), XBIOTECH INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), NANTKWEST INC (NASDAQ), MACROGENICS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), MERUS B V (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), AGENUS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), PROTHENA CORP PLC (NASDAQ), TRANSLATE BIO INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), CUE BIOPHARMA INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), CABALETTA BIO INC (NASDAQ), RECRO PHARMA INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), PERSONALIS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), IVERIC BIO INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), KAMADA (NASDAQ), SERES THERAPEUTICS (NASDAQ), VBI VACCINES INC CDA (NASDAQ), GERON CORP (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), NOVAVAX INC (NASDAQ), XOMA CORP (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), IMV INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), MEDICINOVA INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), AFFIMED N V (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), ATHERSYS INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), CHIASMA INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), GLYCOMIMETICS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), VERASTEM INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), CELYAD ADS EACH REPR 1 ORD (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), ARAVIVE INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), INFLARX N V (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), AXCELLA HEALTH INC (NASDAQ), SAVARA INC (NASDAQ), OTONOMY INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), CHIMERIX INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), VERMILLION INC (NASDAQ), SYNLOGIC INC (NASDAQ), VACCINEX INC (NASDAQ), EQUILLIUM INC (NASDAQ), SESEN BIO INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), ORGENESIS INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), ANPAC BIO MEDICAL SCIENCE CO LTD SPON ADS EACH REPR 1 ORD SHS CLASS A (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), TREVENA INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), SOLIGENIX INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), ADVAXIS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), INMUNE BIO INC (NASDAQ), RESTORBIO INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), VAXART INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), ZAFGEN INC (NASDAQ), CURIS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), TOCAGEN INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), EVOGENE LTD (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), ATYR PHARMA INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), BIOCARDIA INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), OCUGEN INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), PRECIPIO INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), SENESTECH INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), SPHERIX INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ)
Global Peer CSL ASX 147,720.436 55.059 50.994 - 0.815
Global Peer AMGEN-T HKEx 589,807.000 8.965 9.598 7.8255 4.417
Global Peer AGILENT TECHNOLOGIES INC NYSE 25,016.824 79.167 32.745 5.1602 0.758
Global Peer WUXI BIO HKEx 153,530.528 205.554 160.697 15.8041 -
Global Peer SINO BIOPHARM HKEx 139,837.724 13.051 13.545 4.1645 0.658
Global Peer BEIGENE HKEx 98,260.501 - - 9.8040 -
Global Peer Lonza SGX 5,937.453 6.613 6.613 0.6568 4.787
Global Peer GENSCRIPT BIO HKEx 32,037.427 192.665 - 9.0344 -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 3,176.448 50.661 58.177 2.9182 -
Global Peer 3SBIO HKEx 25,272.701 16.706 20.334 2.4909 -
Other Global Peers ALPHAMAB-B (HKEx), HAOHAI BIOTEC (HKEx), FRONTAGE (HKEx), POLYNOVO LIMITED (ASX), AVITA MEDICAL LTD (ASX), MYOVANT SCIENCES LTD (NYSE), MESOBLAST LTD (ASX), VIVA BIOTECH (HKEx), KADMON HLDGS INC (NYSE), ARCUS BIOSCIENCES INC (NYSE), ASCENTAGE-B (HKEx), ASCLETIS-B (HKEx), SINOMAB BIO-B (HKEx), NANOVIRICIDES INC (NYSE American), ESSEX BIO-TECH (HKEx), LEE'S PHARM (HKEx), PFENEX INC (NYSE American), TELIX PHARMACEUTIC (ASX), DPHARMA (Bursa), BBI LIFE SCI (HKEx), NEXT SCIENCE LTD (ASX), LINEAGE CELL THERAPEUTICS INC (NYSE American), NEUREN PHARMACEUTICALS LTD (ASX), CEL-SCI CORP (NYSE American), UNI-BIO GROUP (HKEx), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), IMMUTEP LTD (ASX), ENZO BIOCHEM INC (NYSE), IMUGENE LIMITED (ASX), 22ND CENTURY GROUP INC (NYSE American), PALATIN TECHNOLOGIES INC (NYSE American), CYNATA THERAPEUTICS LTD (ASX), SYNTHETIC BIOLOGICS INC (NYSE American), CT ENTERPRISE (HKEx), BIOTRON (ASX), INVEX THERAPEUTICS LTD NPV (ASX), ARMATA PHARMACEUTICALS INC (NYSE American), BIOSINO BIO-TEC (HKEx), HOLISTA COLLTECH LIMITED (ASX), MEMPHASYS LTD (ASX), KAZIA THERAPEUTICS LIMITED (ASX), ORAGENICS INC (NYSE American), ANTEOTECH LIMITED (ASX), CCP TECHNOLOGIES LTD (ASX), IBIO INC (NYSE American), REGENT PACIFIC (HKEx), GENETIC TECHNOLOGIES (ASX), BIONOMICS LTD (ASX), ACTINOGEN MEDICAL LTD (ASX), ACTINIUM PHARMACEUTICALS INC (NYSE American), INDIA GLOBALIZATION CAPITAL INC (NYSE American), RHINOMED LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), Suntar Eco-City^ (SGX), PATRYS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), REGENEUS LTD (ASX), HAO WEN HLDGS (HKEx), SIENNA CANCER DIAGNOSTICS LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), AIM IMMUNOTECH INC (NYSE American), ADALTA LTD (ASX), BENITEC BIOPHARMA LTD (ASX), ANATARA LIFESCIENCES LTD (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), LIVING CELL TECHNOLOGIES (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), LEAF RESOURCES LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), CRYOSITE (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --1.820
-3.73 %
10 Days --2.040
-4.16 %
20 Days -+5.830
+14.16 %
Medium Term Return 3 Months -+16.270
+52.95 %
6 Months -+40.380
+609.97 %
1 Year -+36.330
+340.49 %
Long Term Return 2 Years -+37.250
+382.05 %
3 Years -+40.380
+609.97 %
5 Years -+39.160
+499.49 %
Annualised Return Annualised --
+43.07 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 6.160 - 51.360 Change From 1 Year Low +40.840 % Change From 1 Year Low (%) +662.99
Change From 1 Year High -4.360 % Change From 1 Year High (%) -8.49
2 Years Range 6.160 - 51.360 Change From 2 Years Low +40.840 % Change From 2 Years Low (%) +662.99
Change From 2 Years High -4.360 % Change From 2 Years High (%) -8.49
5 Years Range 1.921 - 51.360 Change From 5 Years Low +45.079 % Change From 5 Years Low (%) +2346.13
Change From 5 Years High -4.360 % Change From 5 Years High (%) -8.49
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.

Historical Price Data

Date Open High Low Close Volume VWAP
24 Feb 2020 47.050 47.905 46.290 47.000 514,887 -
21 Feb 2020 49.560 49.630 48.070 48.870 308,980 -
20 Feb 2020 50.470 51.130 48.867 49.590 345,338 -
19 Feb 2020 48.970 51.360 48.765 50.520 527,510 -
18 Feb 2020 48.940 49.006 46.520 48.820 578,581 -
14 Feb 2020 49.190 49.390 46.855 48.000 529,739 -
13 Feb 2020 48.990 49.970 48.780 49.290 445,973 -
12 Feb 2020 49.290 49.590 48.580 49.260 402,199 -
11 Feb 2020 49.500 49.550 48.770 49.040 522,552 -
10 Feb 2020 47.450 48.930 47.450 48.770 401,453 -
07 Feb 2020 47.950 48.040 46.725 47.490 581,475 -
06 Feb 2020 47.810 48.000 45.894 47.795 629,676 -
05 Feb 2020 45.810 47.160 45.500 47.160 521,425 -
04 Feb 2020 45.570 45.900 44.595 45.260 800,727 -
03 Feb 2020 42.880 44.960 42.590 44.890 648,915 -
31 Jan 2020 40.700 42.470 40.420 42.420 390,538 -
30 Jan 2020 39.920 41.410 39.660 40.900 285,923 -
29 Jan 2020 41.230 41.580 40.310 40.750 248,507 -
28 Jan 2020 41.100 42.035 40.810 41.170 260,905 -
27 Jan 2020 39.800 41.070 38.850 40.620 403,734 -
24 Jan 2020 41.470 43.080 40.350 41.270 576,839 -
23 Jan 2020 42.530 42.835 39.455 40.740 639,211 -
Summary
Current 2 Weeks
(10 Feb 2020 to 24 Feb 2020)
47.450 51.360 46.290 47.000 4,577,212 -
Previous 2 Weeks
(27 Jan 2020 to 07 Feb 2020)
39.800 51.360 38.850 47.490 4,771,825 -
4 Weeks from
(26 Dec 2019 to 24 Jan 2020)
37.030 51.360 36.430 41.270 15,095,563 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.